Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Coya Therapeutics, Inc.NASDAQ: COYA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $2.2M rose 103.3% year over year, ahead of the +63.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 98.9% from the prior quarter. Over 3 fiscal years it compounded at +174.5% a year.
Context
- Stock-based compensation amounted to 54.0% of revenue in FY2025, down 20.9 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +103.3% holds above the trailing-twelve-month pace of +63.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 4.29M USD
- Year-over-year change
- +61.1%
- 4-year CAGR
- +107.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.29M | +61.1% |
| FY2024 | 2024-12-31 | 2.66M | +205.4% |
| FY2023 | 2023-12-31 | 872.25K | +320.7% |
| FY2022 | 2022-12-31 | 207.35K | -11.1% |
| FY2021 | 2021-12-31 | 233.22K | — |
Stock-Based Compensation vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's LTM Mar 2026 stock-based compensation of $5.41M is the 7th largest of the 11 companies compared; the peer median is $7.57M.
- Its year-over-year change of +63.4% is the highest of 11, against a peer median of -10.7%.
- Stock-based compensation amounts to 68.1% of revenue for COYA, versus a peer median of 138.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.58M | -41.5% | +5.1% | — | |
| LTM Mar 2026 | $14.24M | -76.6% | -23.8% | — | |
| LTM Mar 2026 | $12.55M | -55.6% | -11.3% | 8.0% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $9.87M | -8.9% | +0.8% | 138.2% |
| LTM Mar 2026 | $7.69M | -12.5% | +2.7% | 768.9% | |
| LTM Mar 2026 | $7.45M | -5.5% | -9.2% | 5559.7% | |
| LTM Mar 2026 | $5.41M | +63.4% | +174.5% | 68.1% | |
| LTM Mar 2026 | $2.41M | -6.9% | -9.8% | 33.9% | |
| LTM Mar 2026 | $2.28M | +4.3% | — | — | |
| LTM Mar 2026 | $2.15M | -27.0% | +57.6% | — | |
| LTM Mar 2026 | $1.45M | +61.5% | +10.9% | — | |
| Peer median (excluding COYA) | $7.57M | -10.7% | +0.8% | 138.2% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| Deferred Income Tax | 399.68K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 233.22K | 207.35K | 872.25K | 2.66M | 4.29M |
| Change in Working Capital | 739.17K | 751.84K | (4.64M) | 1.88M | 3.88M |
| Accounts Receivables | 0 | 0 | (7.5M) | 7.5M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 665.17K | 845.28K | 298.82K | 477.45K | (527.01K) |
| Other Working Capital | 74K | (93.45K) | 2.56M | (6.1M) | 4.41M |
| Other Non-Cash Items | (399.68K) | 4.02M | 543.19K | 25K | 2.29M |
| Operating Cash Flow | (3.9M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
| Capital Expenditures | (136.8K) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (525K) | (543.19K) | (25K) | 0 |
| Investing Cash Flow | (136.8K) | (525K) | (543.19K) | (25K) | (1.16M) |
| Debt Repayment | 0 | 10.47M | 0 | 0 | 0 |
| Common Stock Issued | 1.32K | 158 | 38.34M | 14M | 20.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (341.9K) | (1.11M) | 89.95K | 2.02M | 0 |
| Financing Cash Flow | (340.58K) | 9.36M | 38.43M | 16.03M | 20.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.38M) | 1.59M | 26.69M | 5.71M | 8.48M |
| Free Cash Flow | (4.04M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.